Chao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chao Zhang has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Chao Li
Department of Neurosurgery, Qilu Hospital of Shandong University
6 shared publications- Weiguo Li
Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, China
5 shared publications Qianqian Wu
Department of Neurosurgery, Qilu Hospital of Shandong University and Institute of Brain and Brain-Inspired Science, Jinan, China
4 shared publicationsYing Hou
Department of neurology, Qilu Hospital of Shandong University, Jinan, China
4 shared publicationsJinxing Sun
Department of Colorectal Sugery, Zhongshan Hospital Fudan University, Shanghai, China
3 shared publicationsJunheng Jia
Department of Neurosurgery, Qilu Hospital of Shandong University and Institute of Brain and Brain-Inspired Science, Jinan, China
3 shared publications
Latest Publications
- 4 March 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Consumer Electronics
- Vol. PP (00983063) , 1
Hierarchical Dual-Strategy Unlearning for Biomedical and Healthcare Intelligence Using Imperfect and Privacy-Sensitive Medical Data
Large language models (LLMs) exhibit exceptional performance across diverse domains, yet their propensity to memorise training data poses substantial privacy risks, particularly within sensitive healthcare contexts where medical data is often imperfect, insufficiently labelled, or contains privacy-sensitive patient information. Here, we present a hierarchical dual-strategy framework for selective knowledge unlearning in medical LLMs that enables precise removal of specialised knowledge whilst preserving fundamental medical competencies, specifically addressing challenges in biomedical and healthcare intelligence using imperfect data. Our approach synergistically integrates geometric-constrained gradient updates, which selectively modulate parameters encoding target knowledge while safeguarding essential capabilities, with concept-aware token-level interventions that systematically distinguish between preservation-critical and unlearning-targeted tokens through a unified four-level medical concept hierarchy. Through comprehensive evaluation on the MedMCQA dataset targeting surgical knowledge removal, and cross-domain validation on the MHQA dataset encompassing anxiety, depression, trauma, and obsessive-compulsive disorder domains, we demonstrate that our method achieves superior selective unlearning performance (82.7% forgetting rate, 88.5% knowledge preservation) compared to existing approaches. Notably, our framework maintains robust privacy guarantees while requiring modification of only 0.1% of model parameters, establishing a paradigm for privacy-preserving medical AI systems that addresses regulatory compliance, hospital auditability, and ethical imperatives in clinical research environments. This work contributes to advancing biomedical and healthcare intelligence by providing an effective solution for auditing and managing imperfect and privacy-sensitive medical data in real-world clinical applications.
- 4 March 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Consumer Electronics
- Vol. PP (00983063) , 1
Hierarchical Dual-Strategy Unlearning for Biomedical and Healthcare Intelligence Using Imperfect and Privacy-Sensitive Medical Data
Large language models (LLMs) exhibit exceptional performance across diverse domains, yet their propensity to memorise training data poses substantial privacy risks, particularly within sensitive healthcare contexts where medical data is often imperfect, insufficiently labelled, or contains privacy-sensitive patient information. Here, we present a hierarchical dual-strategy framework for selective knowledge unlearning in medical LLMs that enables precise removal of specialised knowledge whilst preserving fundamental medical competencies, specifically addressing challenges in biomedical and healthcare intelligence using imperfect data. Our approach synergistically integrates geometric-constrained gradient updates, which selectively modulate parameters encoding target knowledge while safeguarding essential capabilities, with concept-aware token-level interventions that systematically distinguish between preservation-critical and unlearning-targeted tokens through a unified four-level medical concept hierarchy. Through comprehensive evaluation on the MedMCQA dataset targeting surgical knowledge removal, and cross-domain validation on the MHQA dataset encompassing anxiety, depression, trauma, and obsessive-compulsive disorder domains, we demonstrate that our method achieves superior selective unlearning performance (82.7% forgetting rate, 88.5% knowledge preservation) compared to existing approaches. Notably, our framework maintains robust privacy guarantees while requiring modification of only 0.1% of model parameters, establishing a paradigm for privacy-preserving medical AI systems that addresses regulatory compliance, hospital auditability, and ethical imperatives in clinical research environments. This work contributes to advancing biomedical and healthcare intelligence by providing an effective solution for auditing and managing imperfect and privacy-sensitive medical data in real-world clinical applications.
- Open Access
- 24 November 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1)
MoleProLink-RL: geometric transport for domain-policy reinforcement learning in drug-target interaction prediction
Accurate drug-target interaction (DTI) prediction is vital to modern discovery workflows, yet models trained in one setting often underperform when chemotypes, protein families, or assay conditions shift. MoleProLink-RL addresses this challenge as a model-first solution that couples chemically faithful representations with geometry-aware alignment and stability-aware decision making. The system combines graph-transformer drug encoders and residual protein embeddings with an unsupervised distribution alignment layer that respects molecular similarity through a DTI-aware transport distance complemented by kernel mean embeddings, while a lightweight reinforcement-learning objective regulates ranking stability across latent sub-environments under a small trust region to a supervised reference. Unlike pipelines that bolt adaptation onto frozen features or tune policies post hoc, MoleProLink-RL trains representation, alignment, and decisions end-to-end so that what the model learns to represent directly improves how it prioritizes candidates under shift. We provide a Fisher–Wasserstein view that clarifies why joint updates are safe in parameter space and effective on distribution space, and we validate the approach on Human, C. elegans, and Davis benchmarks with realistic class imbalance, comprehensive ablations, and diagnostics for calibration and interpretability. The result is a practical, data-efficient DTI model that maintains top-of-list precision when conditions change, narrowing the gap between benchmark performance and laboratory impact.
- 24 November 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1)
Open AccessMoleProLink-RL: geometric transport for domain-policy reinforcement learning in drug-target interaction prediction
Accurate drug-target interaction (DTI) prediction is vital to modern discovery workflows, yet models trained in one setting often underperform when chemotypes, protein families, or assay conditions shift. MoleProLink-RL addresses this challenge as a model-first solution that couples chemically faithful representations with geometry-aware alignment and stability-aware decision making. The system combines graph-transformer drug encoders and residual protein embeddings with an unsupervised distribution alignment layer that respects molecular similarity through a DTI-aware transport distance complemented by kernel mean embeddings, while a lightweight reinforcement-learning objective regulates ranking stability across latent sub-environments under a small trust region to a supervised reference. Unlike pipelines that bolt adaptation onto frozen features or tune policies post hoc, MoleProLink-RL trains representation, alignment, and decisions end-to-end so that what the model learns to represent directly improves how it prioritizes candidates under shift. We provide a Fisher–Wasserstein view that clarifies why joint updates are safe in parameter space and effective on distribution space, and we validate the approach on Human, C. elegans, and Davis benchmarks with realistic class imbalance, comprehensive ablations, and diagnostics for calibration and interpretability. The result is a practical, data-efficient DTI model that maintains top-of-list precision when conditions change, narrowing the gap between benchmark performance and laboratory impact.
- Open Access
- 8 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Impact of anti-VZV IgG levels on Parkinson’s disease risk and progression: a Mendelian randomization analysis
Research suggests a potential link between varicella zoster virus (VZV) and Parkinson’s disease (PD), but the causal relationship between anti-VZV IgG levels and PD is not well understood. Using two-sample Mendelian Randomization (MR), we assessed the causal impact of anti-VZV IgG levels on PD risk and progression. Our study found a significant association between higher anti-VZV IgG levels and an increased risk of PD. For PD progression, higher anti-VZV IgG levels were linked to a greater risk of constipation, insomnia, and Restless Legs. These findings remained consistent after sensitivity analyses. In conclusion, our study suggests that elevated anti-VZV IgG levels may contribute to an increased risk and progression of PD, supporting a potential causal link that warrants further mechanistic investigation.
- 8 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-8
Open AccessImpact of anti-VZV IgG levels on Parkinson’s disease risk and progression: a Mendelian randomization analysis
Research suggests a potential link between varicella zoster virus (VZV) and Parkinson’s disease (PD), but the causal relationship between anti-VZV IgG levels and PD is not well understood. Using two-sample Mendelian Randomization (MR), we assessed the causal impact of anti-VZV IgG levels on PD risk and progression. Our study found a significant association between higher anti-VZV IgG levels and an increased risk of PD. For PD progression, higher anti-VZV IgG levels were linked to a greater risk of constipation, insomnia, and Restless Legs. These findings remained consistent after sensitivity analyses. In conclusion, our study suggests that elevated anti-VZV IgG levels may contribute to an increased risk and progression of PD, supporting a potential causal link that warrants further mechanistic investigation.
- Open Access
- 5 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 650-660
The reduction of LEDD leads to visual dysfunction in patients with PD after STN-DBS: a randomized clinical trial
Background: Medication adjustment after deep brain stimulation (DBS) of the subthalamic nucleus (STN) in patients with Parkinson’s disease (PD) may influence visual function. However, no clinical trials have been designed specifically to investigate this effect. Objectives: To compare the effects of levodopa-equivalent daily dose (LEDD) reduction and non-reduction on visual function in patients with Parkinson’s disease (PD) following STN-DBS. Methods: This was a multi-center, prospective, randomized, double-blinded clinical trial. A total of 208 patients with Parkinson’s disease were referred for DBS between June 2019 and July 2021 and analyzed between June 2023 and July 2023. STN-DBS was performed, and the LEDD was reduced in one study arm but not in the other. The primary outcome measure was visual impairment in Parkinson’s disease questionnaire (VIPD-Q) with or without LEDD reduction 12 months postoperatively, and the secondary outcomes included retinal nerve fiber layer (RNFL) thickness, vessel density, eye-tracking system results, contrast sensitivity and visual field. Results: During the short-term follow-up, DBS implantation and stimulation did not significantly affect visual function (VIPD-Q, baseline vs. 1 month, 9.269±8.385 vs. 8.938±7.666, Mann–Whitney U tests; P =0.6746). In the long-term follow-up, the reduction group demonstrated a significant decline in visual function, RNFL thickness, and vessel density after STN-DBS compared with the control group without STN-DBS ( P <0.001). Conclusions: Visual dysfunction, particularly a thinner RNFL and lower vessel density, is related to LEDD reduction after STN-DBS. Prolonged administration of dopamine-mimetic drugs prevents visual symptoms. Thus, physicians should consider LEDD adjustment when patients report visual dysfunction before surgery or severe visual symptoms after STN-DBS.
- 5 August 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 650-660
Open AccessThe reduction of LEDD leads to visual dysfunction in patients with PD after STN-DBS: a randomized clinical trial
Background: Medication adjustment after deep brain stimulation (DBS) of the subthalamic nucleus (STN) in patients with Parkinson’s disease (PD) may influence visual function. However, no clinical trials have been designed specifically to investigate this effect. Objectives: To compare the effects of levodopa-equivalent daily dose (LEDD) reduction and non-reduction on visual function in patients with Parkinson’s disease (PD) following STN-DBS. Methods: This was a multi-center, prospective, randomized, double-blinded clinical trial. A total of 208 patients with Parkinson’s disease were referred for DBS between June 2019 and July 2021 and analyzed between June 2023 and July 2023. STN-DBS was performed, and the LEDD was reduced in one study arm but not in the other. The primary outcome measure was visual impairment in Parkinson’s disease questionnaire (VIPD-Q) with or without LEDD reduction 12 months postoperatively, and the secondary outcomes included retinal nerve fiber layer (RNFL) thickness, vessel density, eye-tracking system results, contrast sensitivity and visual field. Results: During the short-term follow-up, DBS implantation and stimulation did not significantly affect visual function (VIPD-Q, baseline vs. 1 month, 9.269±8.385 vs. 8.938±7.666, Mann–Whitney U tests; P =0.6746). In the long-term follow-up, the reduction group demonstrated a significant decline in visual function, RNFL thickness, and vessel density after STN-DBS compared with the control group without STN-DBS ( P <0.001). Conclusions: Visual dysfunction, particularly a thinner RNFL and lower vessel density, is related to LEDD reduction after STN-DBS. Prolonged administration of dopamine-mimetic drugs prevents visual symptoms. Thus, physicians should consider LEDD adjustment when patients report visual dysfunction before surgery or severe visual symptoms after STN-DBS.
- 9 March 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 123, 106075
Deep brain stimulation of the subthalamic nucleus increases the risk of sialorrhea in patients with advanced Parkinson's disease
- 9 March 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 123, 106075
Deep brain stimulation of the subthalamic nucleus increases the risk of sialorrhea in patients with advanced Parkinson's disease
- Open Access
- 17 November 2023
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 26 (4) , 433-441
Fully Endoscopic Microvascular Decompression for Trigeminal Neuralgia Caused by Vertebrobasilar Artery: A Case Series Review: 2-Dimensional Operative Video
BACKGROUND AND OBJECTIVE: Microvascular decompression (MVD) is the most definitive and preferred surgical treatment for trigeminal neuralgia (TN). Treatment of TN caused by the vertebrobasilar artery (VBA) has been reported to be challenging and less satisfactory in complications and recurrence. Endoscopy has been implemented to provide a comprehensive view of neurovascular conflicts and minimize brain tissue stretch injury while exploring the trigeminal nerve. However, there are few retrospective studies on the treatment of TN caused by VBA by fully endoscopic microvascular decompression (E-MVD). This article aimed to illustrate the safety and efficacy of E-MVD for TN caused by the VBA. METHODS: Clinical data for 26 patients with TN caused by the VBA who underwent E-MVD from 2019 to 2022 were retrospectively analyzed. The characteristics of vertebrobasilar-associated TN were summarized. The safety and efficacy of E-MVD for vertebrobasilar-associated TN were estimated based on the analysis of intraoperative manipulation, postoperative symptom relief, and complications. RESULTS: Intraoperatively, the vertebrobasilar artery was regarded as a direct offending vessel in all 26 patients with TN, the vertebral artery in 18 (69.23%) and the basilar artery in 10 (38.46%). In addition to the vertebrobasilar artery, other vessels involved included the superior cerebellar artery in 12 patients, anterior inferior cerebellar artery in 9, posterior inferior cerebellar artery in 1, and veins in 4. All patients underwent E-MVD, and TN was entirely resolved in 26 (100%) patients immediately postoperatively. During the follow-up period of 12–45 months, no recurrence or serious complications were found. There were no serious postoperative complications, such as cerebellar swelling, intracranial hemorrhage, or death. CONCLUSION: E-MVD for vertebrobasilar-associated TN is effective and safe.
- 17 November 2023
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 26 (4) , 433-441
Open AccessFully Endoscopic Microvascular Decompression for Trigeminal Neuralgia Caused by Vertebrobasilar Artery: A Case Series Review: 2-Dimensional Operative Video
BACKGROUND AND OBJECTIVE: Microvascular decompression (MVD) is the most definitive and preferred surgical treatment for trigeminal neuralgia (TN). Treatment of TN caused by the vertebrobasilar artery (VBA) has been reported to be challenging and less satisfactory in complications and recurrence. Endoscopy has been implemented to provide a comprehensive view of neurovascular conflicts and minimize brain tissue stretch injury while exploring the trigeminal nerve. However, there are few retrospective studies on the treatment of TN caused by VBA by fully endoscopic microvascular decompression (E-MVD). This article aimed to illustrate the safety and efficacy of E-MVD for TN caused by the VBA. METHODS: Clinical data for 26 patients with TN caused by the VBA who underwent E-MVD from 2019 to 2022 were retrospectively analyzed. The characteristics of vertebrobasilar-associated TN were summarized. The safety and efficacy of E-MVD for vertebrobasilar-associated TN were estimated based on the analysis of intraoperative manipulation, postoperative symptom relief, and complications. RESULTS: Intraoperatively, the vertebrobasilar artery was regarded as a direct offending vessel in all 26 patients with TN, the vertebral artery in 18 (69.23%) and the basilar artery in 10 (38.46%). In addition to the vertebrobasilar artery, other vessels involved included the superior cerebellar artery in 12 patients, anterior inferior cerebellar artery in 9, posterior inferior cerebellar artery in 1, and veins in 4. All patients underwent E-MVD, and TN was entirely resolved in 26 (100%) patients immediately postoperatively. During the follow-up period of 12–45 months, no recurrence or serious complications were found. There were no serious postoperative complications, such as cerebellar swelling, intracranial hemorrhage, or death. CONCLUSION: E-MVD for vertebrobasilar-associated TN is effective and safe.
- Open Access
- 13 July 2023
- Published by Springer Nature in Research Square
Parkinson’s disease-related lncRNA PINK1-AS advances glioma oncogenesis by activating IPO5-RAS signaling pathway
Background: Epidemiological studies have demonstrated a higher incidence of gliomas in patients with Parkinson's disease. However, the underlying molecular mechanisms remain unclear, and insights into why and how patients with Parkinson's disease are susceptible to gliomas are essential for advancing novel therapeutic approaches for both diseases. Methods: The Chinese Glioma Genome Atlas (CGGA) database was used to screen Parkinson’s disease-related genes associated with glioma prognosis. The expression of the lncRNA PINK1-AS in the brain tissue of patients with Parkinson’s diseaseand glioma tissues and cells was characterized by quantitative reverse transcription polymerase chain reaction. The efficacy of PINK1-AS knockdown in gliomas was evaluated by assessing cell proliferation, migration, cell cycles, and experimental xenografts. To establish the relationship between the PINK1-AS, miR-200a-3p, and IPO5 genes, RNA immunoprecipitation, RNA probe pull-down, luciferase reporter, and fluorescence in situ hybridization assays were performed. Results: PINK1-AS expression was anomalously elevated in brain tissue of patients with Parkinson’s disease, glioma tissues, and cell lines compared to normal brain tissue, and the overall survival time was reduced in patients with glioma with high PINK1-AS expression. PINK1-AS knockdown remarkably suppressed glioma malignant phenotypes, including cell promotion, metastasis, and aggression in vitro and xenograft tumor generation in vivo. Furthermore, PINK1-AS may serve as a pool for miR-200a-3p, thereby de-repressing IPO5 and activating the RAS signaling pathway. Conclusions: PINK1-AS, highly expressed in both Parkinson's disease and glioma, regulates IPO5 expression by downregulating miR-200a-3p and activating the RAS signaling pathway.
- 13 July 2023
- Published by Springer Nature in Research Square
Open AccessParkinson’s disease-related lncRNA PINK1-AS advances glioma oncogenesis by activating IPO5-RAS signaling pathway
Background: Epidemiological studies have demonstrated a higher incidence of gliomas in patients with Parkinson's disease. However, the underlying molecular mechanisms remain unclear, and insights into why and how patients with Parkinson's disease are susceptible to gliomas are essential for advancing novel therapeutic approaches for both diseases. Methods: The Chinese Glioma Genome Atlas (CGGA) database was used to screen Parkinson’s disease-related genes associated with glioma prognosis. The expression of the lncRNA PINK1-AS in the brain tissue of patients with Parkinson’s diseaseand glioma tissues and cells was characterized by quantitative reverse transcription polymerase chain reaction. The efficacy of PINK1-AS knockdown in gliomas was evaluated by assessing cell proliferation, migration, cell cycles, and experimental xenografts. To establish the relationship between the PINK1-AS, miR-200a-3p, and IPO5 genes, RNA immunoprecipitation, RNA probe pull-down, luciferase reporter, and fluorescence in situ hybridization assays were performed. Results: PINK1-AS expression was anomalously elevated in brain tissue of patients with Parkinson’s disease, glioma tissues, and cell lines compared to normal brain tissue, and the overall survival time was reduced in patients with glioma with high PINK1-AS expression. PINK1-AS knockdown remarkably suppressed glioma malignant phenotypes, including cell promotion, metastasis, and aggression in vitro and xenograft tumor generation in vivo. Furthermore, PINK1-AS may serve as a pool for miR-200a-3p, thereby de-repressing IPO5 and activating the RAS signaling pathway. Conclusions: PINK1-AS, highly expressed in both Parkinson's disease and glioma, regulates IPO5 expression by downregulating miR-200a-3p and activating the RAS signaling pathway.
- 21 June 2023
- Published by Elsevier in World Neurosurgery
- Vol. 177, e343-e353
Visual Dysfunction is a Risk Factor of Postoperation Delirium in Parkinson Disease
- 21 June 2023
- Published by Elsevier in World Neurosurgery
- Vol. 177, e343-e353
Visual Dysfunction is a Risk Factor of Postoperation Delirium in Parkinson Disease
- Open Access
- 5 January 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (1) , 103
Acute Visual Impairment in a Patient with Parkinson’s Disease after Successful Bilateral Subthalamic Nucleus Deep Brain Stimulation with Low-Dose Levodopa: A Case Report
Background: Subthalamic nucleus deep brain stimulation (STN-DBS) is widely used for the treatment of primary motor symptoms in patients with Parkinson’s disease (PD). Further, recent evidence suggests that STN-DBS may relieve a few ophthalmic symptoms in PD, such as eye-blink rate and the flexibility of eye saccades. However, its exact effect on visual function remains unknown. Herein, we report the case of a patient with PD who underwent STN-DBS and experienced visual symptoms following levodopa reduction. Case presentation: A 63-year-old male patient with PD developed severe visual impairment after six months of high-frequency STN-DBS. His symptoms resolved after adjusting the levodopa dose prescribed to the patient. Conclusions: This case report suggests that DBS is beneficial in patients with PD in terms of eye-blink rate. However, the rapid reduction of medication after STN-DBS may lead to retinal atrophy and the shrinkage of vessel density in the ocular fundus. Thus, neurosurgeons should pay close attention to patients with visual symptoms when adjusting levodopa dosages.
- 5 January 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (1) , 103
Open AccessAcute Visual Impairment in a Patient with Parkinson’s Disease after Successful Bilateral Subthalamic Nucleus Deep Brain Stimulation with Low-Dose Levodopa: A Case Report
Background: Subthalamic nucleus deep brain stimulation (STN-DBS) is widely used for the treatment of primary motor symptoms in patients with Parkinson’s disease (PD). Further, recent evidence suggests that STN-DBS may relieve a few ophthalmic symptoms in PD, such as eye-blink rate and the flexibility of eye saccades. However, its exact effect on visual function remains unknown. Herein, we report the case of a patient with PD who underwent STN-DBS and experienced visual symptoms following levodopa reduction. Case presentation: A 63-year-old male patient with PD developed severe visual impairment after six months of high-frequency STN-DBS. His symptoms resolved after adjusting the levodopa dose prescribed to the patient. Conclusions: This case report suggests that DBS is beneficial in patients with PD in terms of eye-blink rate. However, the rapid reduction of medication after STN-DBS may lead to retinal atrophy and the shrinkage of vessel density in the ocular fundus. Thus, neurosurgeons should pay close attention to patients with visual symptoms when adjusting levodopa dosages.
- Open Access
- 1 December 2021
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 17, 3727-3733
Effect of Deep Brain Stimulation on Female Parkinsonian Patients with Lower Urinary Tract Symptoms
Purpose: This study aimed to investigate the characteristics of urodynamics in female parkinsonian patients with lower urinary tract symptoms (LUTS) and evaluate the outcomes of deep brain stimulation (DBS) based on overactive bladder (OAB) scores and quality of life (QOL) scores. Patients and Methods: Urodynamic assessment was performed in 20 female parkinsonian patients with LUTS. OAB scores and QOL scores were collected before and 6 months after DBS treatment (The target of DBS is STN). We evaluated the related factors affecting QOL score and also the changes in QOL score after DBS treatment. Results: The mean age of 20 patients was 60.6± 6.3 years, with 65% of patients identified with OAB in urodynamic studies. The mean OAB total score and QOL score at baseline were 7.3± 3.7 and 5.0± 1.1, respectively. Four items in the OAB score were found to be independent factors and they influenced the baseline QOL scores. Six months after DBS treatment, the OAB total score and the QOL score were significantly decreased (3.7± 3.2 (p = 0.002) and 3.4± 1.4 (p < 0.001), respectively). Improvements in OAB item 2 (nocturia) and item 3 (urgency) scores were found to be independent factors, which had an influence on the improvement in QOL scores from multivariate analysis. Improvement of OAB item 2 (nocturia) exhibited the greatest influence on improvement in the QOL score. After DBS treatment, 40% of the patients showed significant improvement in urination symptoms (≥ 2 points reduction in QOL score), 30% of the patients showed mild improvement (1 point reduction in QOL score), and 30% patients showed no improvement (no change in QOL score). No patients exhibited worsening urination symptoms. Conclusion: Most parkinsonian female patients with lower urinary tract symptoms were diagnosed with OAB. DBS treatment improved OAB symptoms. Improvement of nocturia and urgency positively impacts the QOL of female parkinsonian patients.
- 1 December 2021
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 17, 3727-3733
Open AccessEffect of Deep Brain Stimulation on Female Parkinsonian Patients with Lower Urinary Tract Symptoms
Purpose: This study aimed to investigate the characteristics of urodynamics in female parkinsonian patients with lower urinary tract symptoms (LUTS) and evaluate the outcomes of deep brain stimulation (DBS) based on overactive bladder (OAB) scores and quality of life (QOL) scores. Patients and Methods: Urodynamic assessment was performed in 20 female parkinsonian patients with LUTS. OAB scores and QOL scores were collected before and 6 months after DBS treatment (The target of DBS is STN). We evaluated the related factors affecting QOL score and also the changes in QOL score after DBS treatment. Results: The mean age of 20 patients was 60.6± 6.3 years, with 65% of patients identified with OAB in urodynamic studies. The mean OAB total score and QOL score at baseline were 7.3± 3.7 and 5.0± 1.1, respectively. Four items in the OAB score were found to be independent factors and they influenced the baseline QOL scores. Six months after DBS treatment, the OAB total score and the QOL score were significantly decreased (3.7± 3.2 (p = 0.002) and 3.4± 1.4 (p < 0.001), respectively). Improvements in OAB item 2 (nocturia) and item 3 (urgency) scores were found to be independent factors, which had an influence on the improvement in QOL scores from multivariate analysis. Improvement of OAB item 2 (nocturia) exhibited the greatest influence on improvement in the QOL score. After DBS treatment, 40% of the patients showed significant improvement in urination symptoms (≥ 2 points reduction in QOL score), 30% of the patients showed mild improvement (1 point reduction in QOL score), and 30% patients showed no improvement (no change in QOL score). No patients exhibited worsening urination symptoms. Conclusion: Most parkinsonian female patients with lower urinary tract symptoms were diagnosed with OAB. DBS treatment improved OAB symptoms. Improvement of nocturia and urgency positively impacts the QOL of female parkinsonian patients.